Day: February 25, 2024

Figure 1Photo of 5E lab assistant testing boric acid head-grade.Figure 2Photo of wellfield DCS Feb 2024.Figure 3Photo of 5E investor booth at Mines and Money Miami conference.Measurable progress continues towards near-term plant completion Company remains on track to commence commercial operations in CY Q2 2024 at the 5E Boron Americas Complex in California HESPERIA, Calif., Feb. 25, 2024 (GLOBE NEWSWIRE) — 5E Advanced Materials, Inc. (Nasdaq: FEAM) (ASX: 5EA) (5E or the Company), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas Complex, provided an update on mining operations and related activities as it moves closer to initial production at the Company’s 5E Boron Americas Complex. “This is an exciting time for all stakeholders of the Company...

BRISBANE, Australia, Feb. 26, 2024 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX”), a leading battery materials and technology company, today announced that members of the executive team are scheduled to participate in the following upcoming investor events in February and March 2024:Baird 2024 Vehicle Technology & Mobility Conference to be held virtually on February 29, 2024; and Gabelli Funds 15th Annual Specialty Chemical Symposium to be held March 14, 2024, in New York City.NOVONIX management will be available to host one-on-one and group investor meetings during the conferences. Presentation materials and available webcast links will be available prior to each event on the NOVONIX investor relations website. This announcement has been authorized for release by NOVONIX Chairman, Admiral Robert...

VANCOUVER, British Columbia, Feb. 25, 2024 (GLOBE NEWSWIRE) — Yintai Gold Co., Ltd (000975.CN) (“Yintai“) and Osino Resources Corp. (TSX:OSI.V) (NSX:OSN) (FSE:RSR1) (“Osino“) are pleased to announce that they have entered into a binding arrangement agreement (the “Yintai Arrangement Agreement“), pursuant to which Yintai will acquire all of the outstanding common shares of Osino (each, an “Osino Common Share“) by way of a plan of arrangement (the “Yintai Arrangement“), for cash consideration of C$1.90 for each Osino Common Share, valuing Osino at approximately C$368 million. At closing of the Yintai Arrangement, Osino’s portfolio will consist only of gold related assets located in Namibia, primarily the Twin Hills Gold Project in central Namibia as well as exploration projects...

Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reaction The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies Allergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and safety of Xolair® (omalizumab) in patients allergic to peanuts and at least two other common foods...

LUXEMBOURG, Feb. 25, 2024 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) (“Tenaris”) announced today that pursuant to its Share Buyback Program (the “Program”) announced on November 1, 2023, covering up to $1.2 billion to be executed in the open market with the intent to cancel the ordinary shares acquired through the Program, Tenaris has entered into a non-discretionary buyback agreement with a primary financial institution (the “Bank”). The Bank will make its trading decisions concerning the timing of the purchases of Tenaris’s ordinary shares independently of and uninfluenced by Tenaris and will act in compliance with applicable rules and regulations, including the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 (the “Regulations”). Under the buyback agreement,...

SCOTTSDALE, Ariz., Feb. 24, 2024 (GLOBE NEWSWIRE) — Adamas One Corp. (Nasdaq: JEWL) (“Adamas One,” “Adamas” or the “Company”), The Original Lab-Grown Diamond Company™, a high-tech company that leverages proprietary technology to produce high-quality, single-crystal, Lab-Grown Diamonds for jewelry and diamond materials for technology and other industrial uses, provides a shareholder update from our CEO below: Upon closing out our first year as a publicly traded company, listed on the NASDAQ exchange, we wanted to reach out to you, our shareholders, with an update on our business and to thank you for both your support and patience. Being a young company listed in a difficult market has been challenging, but we learned, adjusted and now we are looking forward to a good year ahead. At Adamas One Corp, our strategy to build a...